Leaders of Finance and Economic Commission of Jiangxi Provincial People's Congress visited our company for investigation
On the morning of December 28, 2020, walking in Chaoyang, Liu Cuilan, member of the Standing Committee of Jiangxi Provincial People's Congress and vice chairman of the Finance and Economic Commission, led relevant leaders of various departments, accompanied by Chen Qingshou, deputy secretary of the CPC Working Committee and director of the management committee of Jinggangshan Economic and Technological Development Zone, and Zhang Zhifu, deputy director of the management committee of Jinggangshan Economic and Technological Development Zone, to visit our company for research and guidance.
Yao Xiaodong, the general manager of the company, warmly received and went to the front line of the company for investigation and research with the leaders of the delegation. The delegation led by the Finance and Economic Committee of the Provincial People's Congress watched and listened to the site of the company's tetanus antitoxin production line, raw material warehouse and finished product warehouse. He said that since the advent of the biomedical industry, Jiangxi Bio has timely tracked the cutting-edge technology of antitoxin serum, deeply cultivated the production and research of the biomedical tetanus antitoxin industry, had unique insights into the development law of the biomedical industry, and had keen insight into investment opportunities in the industry. Jiangxi Biotech's professional team actively cooperates with domestic and foreign universities and academicians and experts to provide patients with professional biomedical industry prevention and treatment services, which has been highly recognized by customers. President Yao introduced the research and development progress of the company's new products to the delegation in detail, showed the pilot test samples of new products, and said that the company has a large number of first-hand resources and practical experience in antiserum products as support for research. Through the company's in-depth development, it will lead the company to enter a new development platform.
Liu Cuilan, member of the Standing Committee of the Provincial People's Congress and vice chairman of the Finance and Economic Commission, listened carefully and inquired about the development of the company in detail, and had in-depth exchanges with the company's principal. Yao Xiaodong, the company's general manager, made introductions and answers one by one. In this way, Yao Xiaodong, the general manager, made a careful and detailed report on the company's product research and development, development status, technical level, research and development capability, platform construction and future development plan.
Yao Xiaodong, General Manager, said that currently, biological products mainly include vaccines for prevention, antibodies for treatment and biological diagnostic reagents. It plays an increasingly important role in the diagnosis, prevention, treatment and even elimination of diseases, and in protecting human health and prolonging life span. The company will take animal immunoglobulin antibody preparation as the leading role, and build itself into one of the most valuable and competitive modern export-oriented biopharmaceutical enterprises in the world. The leaders of the Finance and Economic Commission of the Provincial People's Congress praised the development and current situation of the company. The inspection team of the Finance and Economic Commission pointed out that the pharmaceutical industry has become the focus of competition among the world's economic powers. Many countries in the world regard the establishment of the pharmaceutical industry as a symbol of national prosperity. The continuous discovery of new drugs and the great progress in treatment methods have led to great changes in the pharmaceutical industry. It is hoped that our company will seize the new opportunity of market economy development, promote the development of biological products industry with scientific and technological innovation, and make the biological medicine industry more refined, more refined and stronger with scientific and technological innovation. Chen Qingshou, director of the JKQ Management Committee, said during the inspection that the biopharmaceutical industry is a high input, high-risk, high-tech, long cycle enterprise, and a knowledge intensive, high technology content, highly integrated and mutually penetrating emerging industry. The company must closely follow the latest trend of foreign biomedical development and research, closely focus on the establishment of biotechnology emerging industries and the transformation of traditional industries to develop the company's biotechnology drugs, especially to strengthen the research of those projects that the company has scientific and technological advantages and resource advantages, enhance the ability of technological innovation and product innovation, and gradually form our region's superior technologies and products in the biomedical field.